Morewood and ItxM link up on blood-clotting test:
This article was originally published in Clinica
Morewood Molecular Sciences has entered into a research and development project with the Institute for Transfusion Medicine (ITxM) to develop and validate a microarray system that Morewood claims could improve current blood-clotting tests by "multiple orders of magnitude". The new chip will simultaneously assay hundreds of enzyme reactions using only microlitre quantities of a blood sample, in contrast to the large quantities of blood required to perform a number of similar tests today, says the Pittsburgh, Pennsylvania firm.
You may also be interested in...
Biogen value-based contract with UPMC Health Plan ties payments to patient-reported outcomes for Tecfidera and Avonex. The company may seek something similar for Vumerity.
As interest in immune/inflammatory disease increases and savings achieved dip, payer focus on patient-reported outcomes for contracts reflects shift in focus, Avalere survey suggests.
After an eleventh-hour win last year that saw Congress repeal the medical device excise tax, AdvaMed is going more global. CEO Scott Whitaker sat down with Medtech Insight for a lengthy chat about what the lobby group will focus on in 2020, including reimbursement challenges, the upcoming medical device user-fee negotiations, and negotiations with governments that are key to the industry ecosystem.